Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bacitracin

FDA-approved product (ointment, ophthalmic), marketed as Baci-Rx, Baciguent, Bacitracin and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bacitracin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Burn
  • Eye infection
  • Infection
  • Inflammation
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other antibacterials; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX10; WHO ATC D06AX05; WHO ATC R02AB04; WHO ATC S01AA32

Repurposing investigation

Bacitracin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA82.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli65.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bacitracin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bacitracin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds

    NCT00479193 · start 2006-10

    Registered record
    Registry ID
    NCT00479193
    Conditions
    Burns
    Interventions
    bacitracin/xeroform; Polymem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2006-10
    Completion
    2008-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns
    Interventionbacitracin/xeroform; Polymem
    PhasePhase 1
    Registry statusWithdrawn

  • Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy

    NCT00695578 · start 2006-10

    Registered record
    Registry ID
    NCT00695578
    Conditions
    Actinic Keratosis
    Interventions
    Biafine; Polysporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2008-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionBiafine; Polysporin
    PhasePhase 4
    Registry statusCompleted

  • Nasospore Stent For Use in Enodscopic Sinus Surgery

    NCT00671541 · start 2006-03

    Registered record
    Registry ID
    NCT00671541
    Conditions
    Chronic Sinusitis
    Interventions
    Merogel Nasal Stent and Nasopore Stent; Nasopore Stent and either Gentamycin or Bacitracin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2006-03
    Completion
    2012-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Sinusitis
    InterventionMerogel Nasal Stent and Nasopore Stent; Nasopore Stent and either Gentamycin or Bacitracin
    PhasePhase 4
    Registry statusWithdrawn

  • Use of Amnion on Partial Thickness Burns

    NCT00674999 · start 2005-06

    Registered record
    Registry ID
    NCT00674999
    Conditions
    Burn
    Interventions
    Amnion; Amnion; Polysporin/Bacitracin/Mycostatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2005-06
    Completion
    2008-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn
    InterventionAmnion; Amnion; Polysporin/Bacitracin/Mycostatin
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Clinical Evaluation of Bacitracin

    NCT00132600 · start 2005-04

    Registered record
    Registry ID
    NCT00132600
    Conditions
    Allergic Contact Dermatitis
    Interventions
    bacitracin (allergen)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Contact Dermatitis
    Interventionbacitracin (allergen)
    PhasePhase 2
    Registry statusCompleted